Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We are headquartered in the UK and we also have operations in Germany and the US.
Freeline was founded in 2015 and builds upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL.
With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments.
If you are interested in joining our team and help make our life-changing vision a reality, go to our website for further information.
Our mission: to be life changers.
Please read our Community Guidelines before engaging with us on LinkedIn: https://www.freeline.life/about-us/freeline-social-media-community-engagement-guidelines/
Please note, this page is intended for UK audiences.
Location: United Kingdom, England, Stevenage
Employees: 201-500
Phone: +64 22 452 8107
Total raised: $265.584353M
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Syncona Pa... | synconaltd... |
| - | UCL Techno... | ucltf.co.u... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.03.2022 | - | $26.1M | - |
| 05.07.2020 | Series C | $123.55882... | - |
| 19.06.2018 | Series B | $115.92553... | - |
Mentions in press and media 12
| Date | Title | Description | Source |
| 22.11.2023 | Medtronic isn’t afraid of Wegovy’s potential to disrupt | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 09.05.2023 | Biotech Ascend Gene & Cell Therapies raises £105m | London-based biotech firm Ascend Gene & Cell Therapies has raised $132.5m (£105.1m) for its gene... | uktech.new... |
| 13.02.2023 | Freeline announces the closing of sale of its CMC-focused Ge... | Freeline is a clinical-stage biotechnology company developing transformative adeno-associated viru... | ucltf.co.u... |
| 20.01.2023 | Freeline publishes preclinical proof-of-concept data for FLT... | Freeline is a clinical-stage biotechnology company developing transformative gene therapies for pe... | ucltf.co.u... |
| 15.03.2022 | Freeline Closes $26.1 Million Registered Direct Offering of ... | LONDON, March 15, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “C... | globenewsw... |
| 10.03.2022 | Freeline Announces $26.1 Million Registered Direct Offering ... | LONDON, March 11, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “C... | globenewsw... |
| 07.08.2020 | Freeline Therapeutics makes its NASDAQ debut | Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy com... | ucltf.co.u... |
| 24.07.2020 | British biotech Freeline raises €106 million for its curativ... | - | vcbay.news... |
| 06.07.2020 | British biotech Freeline secures €106 million for its curati... | UK-based Freeline, a biotechnology startup focused on developing curative gene therapies for chronic... | eu-startup... |
| 05.07.2020 | Freeline Raises $120M in Series C Financing | Freeline, a Stevenage, UK-based biotechnology company focused on developing curative gene therapies ... | finsmes.co... |
Show more